ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 336

Patient–Reported Barriers to Achieving Rheumatoid Arthritis Disease Control

Maria I. Danila1, Eric M. Ruderman2, Leslie R Harrold3, Joshua A. Melnick1, Ronan O'Beirne1, Monika M. Safford4, Joel Kremer5 and Jeffrey R. Curtis6, 1University of Alabama at Birmingham, Birmingham, AL, 2Northwestern University Feinberg School of Medicine, Chicago, IL, 3University of Massachusetts Medical School, Worcester, MA, 4Weill Cornell Medical College, New York, NY, 5Corrona, LLC, Southborough, MA, 6Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 5, 2017

Title: Patient Outcomes, Preferences, and Attitudes Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Many patients with RA do not achieve guideline-recommended treat-to-target (T2T) goals in clinical practice. There is a paucity of data regarding the challenges that patients face when attempting to achieve better control of their RA disease activity. In this study we sought to identify and prioritize patient-perceived barriers to achieving RA disease activity control.

Methods: Participants were recruited from the within the Consortium of Rheumatology Researchers of North America (Corrona) registry by email and invited to participate in 4 nominal groups. Each group generated a list of barriers that made it challenging for patients to control their RA disease activity. All generated items were combined in a single dataset and subjected to a card sort procedure to create common themes. A random sample of patients with RA enrolled in Corrona were invited by email to complete a compensated online survey and asked to rank their top 3 barriers. A weighted score was assigned for each barrier by considering the number of respondents who ranked it and the priority rank they assigned. The barriers were sorted into domains. The survey also included knowledge items about T2T strategy and attitudes about RA treatment.

Results: Four nominal groups with 37 RA patients identified 17 themes to achieving control of RA activity. We sent 1567 email invitations to complete the survey and 463 patients with RA responded within 3 weeks. Demographic and clinical data was available for 1331 persons, 383 of whom responded to the survey. There were no differences in age, sex, or disease duration between survey- respondents and non-respondents. A higher proportion of respondents were college-educated. A total of 289 (76%) respondents considered RA to be a high priority for their health, 193 (51%) reported being familiar with T2T as a treatment strategy, and 233 (75%) agreed that it is important to accept the risk of side effects now in order to improve the chance of being healthy in the future. Among the challenges to controlling RA disease activity, the domain that received the highest score was unpredictability of RA and its treatment, which comprised the following barriers: unpredictability of how RA may progress, medication risk aversion, effectiveness, and safety/tolerability concerns (Figure). Symptoms and illness burden domain received the second highest score, followed by the health system domain (Figure).

Conclusion: Important patient-perceived barriers to achieving RA disease control include unpredictability of how RA may progress, medication risk aversion, cost of RA care and RA physical limitations. Addressing these barriers, when possible, may improve goal-directed RA care.

 

 

 


Disclosure: M. I. Danila, Pfizer IGLC, 2; E. M. Ruderman, AbbVie, Amgen, BMS, GSK, Janssen, Eli Lilly and Company, Novartis, Pfizer, Roche/Genentech, 5; L. R. Harrold, Corrona, 1,Pfizer Inc, 2,Roche Pharmaceuticals, 5,Corrona, 3; J. A. Melnick, None; R. O'Beirne, Pfizer, Inc, 2; M. M. Safford, Amgen, 5; J. Kremer, Abbvie, Amgen, BMS, Genentech, GSK, Eli Lilly and Company, Novartis,Pfizer, 5,Abbvie, Genentech, Eli Lilly and Company, Novartis, Pfizer, 2,Genentech and Biogen IDEC Inc., 8,Corrona, 1,Corrona, 3; J. R. Curtis, AbbVie, Roche/Genentech, BMS, UCB, Myraid, Lilly, Amgen, Janssen, Pfizer, Corrona, 5,Amgen, Pfizer, Crescendo Bio, Corrona, 9.

To cite this abstract in AMA style:

Danila MI, Ruderman EM, Harrold LR, Melnick JA, O'Beirne R, Safford MM, Kremer J, Curtis JR. Patient–Reported Barriers to Achieving Rheumatoid Arthritis Disease Control [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/patient-reported-barriers-to-achieving-rheumatoid-arthritis-disease-control/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/patient-reported-barriers-to-achieving-rheumatoid-arthritis-disease-control/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology